Quantum BioPharma Receives 'Buy' Rating on Lucid-MS Potential

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has drawn a bullish stance from Rodman & Renshaw, which initiated coverage with a 'Buy' rating and an $8.00 price target. The optimism centers on the company's lead drug candidate, Lucid-MS, a potentially first-in-class non-immunomodulatory small molecule designed to address neurodegeneration and disability progression in progressive multiple sclerosis (MS). This is a particularly challenging area of treatment, as current therapeutic options remain limited and often fail to halt the relentless progression of the disease.

The analyst's $8.00 price target reflects a valuation of Quantum BioPharma's development pipeline, with Lucid-MS at the core. The drug candidate has shown promise in preclinical models, demonstrating the ability to prevent and reverse myelin degradation—the underlying mechanism of MS. This mechanism of action sets it apart from existing immunomodulatory therapies, which primarily target inflammation rather than the neurodegenerative aspects of the disease.

The significance of this rating lies in the potential of Lucid-MS to fill a critical gap in MS treatment. Progressive MS, which includes primary progressive and secondary progressive forms, is characterized by a steady worsening of neurological function. Patients often face a lack of effective options, making the development of novel therapies like Lucid-MS particularly important. If successful in clinical trials, Lucid-MS could offer a new approach to slowing or even reversing disability progression, which would be a major advancement in the field.

Quantum BioPharma is dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS. The compound is a patented new chemical entity that has shown in preclinical models to prevent and reverse myelin degradation, providing a strong scientific rationale for its potential in MS.

Beyond Lucid-MS, Quantum BioPharma has also developed UNBUZZD(TM), an over-the-counter product aimed at alcohol misuse. The company spun out the OTC version to Unbuzzd Wellness Inc. (UWI), retaining a 19.48% ownership stake as of June 30, 2026. The agreement includes royalty payments of 7% of sales until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products for pharmaceutical and medical uses, ensuring it can capitalize on future opportunities in this space.

The 'Buy' rating and price target from Rodman & Renshaw could influence investor sentiment and bring greater attention to Quantum BioPharma's pipeline. This is especially relevant in the biotech sector, where analyst endorsements can significantly impact a company's visibility and access to capital. For more information on Lucid-MS, interested parties can visit https://nnw.fm/8uqwL.

The latest news and updates relating to QNTM are available in the company's newsroom at https://nnw.fm/QNTM.